Startups, Venture

Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline

Deals, Immuno-oncology

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

People, R&D

Rattled by setbacks, Celgene turns to ex-Merck R&D star Alise Reicin to repair its damaged development rep
More news caret

calendar Protocols

Quick hits from around the biopharma web

Oct 23

NeoGenomics spends $125M to expand ops; Cara hires Celgene exec as CMO

Oct 22

Dupixent wins FDA OK for asthma; Seres poaches new CMO from AstraZeneca

Oct 18

Takeda gets Japanese antitrust regulators' blessing for Shire deal; France's Acticor Biotech raises €15.3M for stroke drug

Oct 17

Novotech beefs up Asia-Pacific CRO offering with new buyout as region’s biopharma business booms

More Protocols caret

person Peer Review

Weekly biopharma careers news report

Oct 19

Medivir taps ex-Acadia chief Uli Hacksell as interim CEO; Merck onboards chief digital officer

Oct 12

Perrigo taps ex-tobacco exec as new CEO; Dana Farber T cell investigator Nick Haining joins Merck

Oct 5

Belgian upstart Rewind taps Ian Reynolds as CEO; Robert Foster takes the reins at ContraVir

Oct 1

Ian Read taps his carefully groomed successor Albert Bourla as the next Pfizer CEO. What's his future look like?

Sep 28

Fred Aslan returns to biotech as president of Vividion; Zai Lab scoops Portola's Tao Fu to spearhead US operations

Sep 21

Ex-Cascadian chief Scott Myers lands at BioClin; Kodiak woos Genentech vet Jason Ehrlich for CMO role

Sep 14

Top scientist Thor Voigt vaults to CMO role at Boehringer Ingelheim; Celgene's Scott Smith tapped as president at BioAtla

Sep 7

Ovid exec Yaron Werber crosses back to Cowen; Saqib Islam promoted to SpringWorks' first CEO slot

More peer review caret

Dollar Premium

Winners and losers at #ESMO18: AstraZeneca’s Lynparza scores ‘spectacular’ results for frontline ovarian cancer; Merck advocates value of its STING drug MK-1454 as a combo with Keytruda — but it won't be an easy sale; Roche/Genentech come up behind Loxo/Bayer with their own challenge on tissue-agnostic cancer drugs

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

Global reach: The top 25 biopharma companies in the world

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

bullhorn Bioregnum

The view from John Carroll

Oct 3

Sarepta shares yo-yo in the red on another glimpse of stellar results for Duchenne MD gene therapy — what gives?

Sep 13

Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important

Sep 6

Juno will pay $24M to settle the JCAR015 scandal — but don’t expect that to change industry attitudes on reporting snafus

Aug 13

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

More opinion caret

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

ENDPOINTS NEWS John Carroll a day

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

Reuters Reuters Editorial a day

Biogen Q3 2018 Revenues Increased 12% to $3.4 Billion

Biogen a day

AstraZeneca digs deeper into cancer with Innate stake

Reuters Ben Hirschler a day

Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug

ENDPOINTS NEWS Endpoints Staff a day

Xconomy: With $90M Round, Stoke Eyes a "Spinraza For Epilepsy" And a 2019 IPO

Xconomy Ben Fidler a day

AstraZeneca deepens partnership with Innate Pharma

Financial Times a day

An integrative tissue-network approach to identify and test human disease genes

Nature Biotechnology Victoria Yao a day

Thousands Of Swedes Are Inserting Microchips Under Their Skin

NPR.org a day

Xconomy: ESMO '18: Precision Meds, Breast, Lung, and More from the Cancer Front

Xconomy Alex Lash a day

timer Latest

New York Times

A Centennial of Death: The Great Influenza Pandemic of 1918

IN

Vaccine confidence low in Europe, raising disease outbreak risk

SWI swissinfo.ch

Novartis leukaemia drug approved in Switzerland

Benzinga

Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

The Guardian

Overuse of antibiotics 'risks return to dark ages of life-threatening surgery'

Biogen

Biogen Q3 2018 Revenues Increased 12% to $3.4 Billion

Abingworth

Abingworth Appoints Jackie Grant as Principal

Xconomy

Xconomy: With $90M Round, Stoke Eyes a "Spinraza For Epilepsy" And a 2019 IPO

FierceBiotech

Takeda buys stake in Enterome's microbiome Crohn's drug

Reuters

AstraZeneca digs deeper into cancer with Innate stake

fire Hot This Week

1

WSJ

A Billionaire Pledges to Fight High Drug Prices, and the Industry Is Rattled

2

Forbes

Researchers Behind Spinraza Win Breakthrough Prize

3

STAT

Novartis buys Endocyte for $2.1 billion, and an outspoken critic admits he was wrong

4

Novartis

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms

5

ClinicalTrials

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov

6

STAT

Cartoons offer a peek into cancer immunotherapy - and scientists' minds - STAT

7

Open Reading Frame

Endocyte - And now for something completely different

8

STAT

Head of IBM Watson Health leaving post after company stumbles, growing criticism

9

STAT

Mirati undersells concerning data on its lung cancer immunotherapy

10

STAT

Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back